Greg Zumach, PharmD, BCPS

Clinical Assistant Professor with a research focus in IBD and leadership UNMC. You'll see tweets about my hometown Chicago Cubs. He/Him/His

[UNMC COP @UnmcCop]

Congratulations to Dr. Downes & Dr. Zumach on completing iLEAD, a program for UNMC Faculty to advance leadership skills and performance, within and outside our organization.

[Shubha Bhat, PharmD @GI_PharmD]

#IBD #PharmDs, check out this great opportunity! Applications due in 1️⃣ week! @MRegueiroMD @IBD_FloMD @IBDBen @CleClinicRxRes @accpGILNprn @ACCP @ASHPOfficial @AmCollegeGastro @AGA_Gastro

[David Choi, PharmD @IBDPharmD]

Super excited to share our recent publication evaluating #pharmacist directed treat to target for #IBD patients! IBD pharmacists can play an important role to help optimizing patient outcomes! #GITwitter @IBDMD @UChicagoGI @UChicagoIBD

https://t.co/BvjCU5Cla6

[Greg Zumach, PharmD, BCPS @GZPharmD]

IBD Treatment 101 was an awesome session. It approachable to those that are just entering the field and applicable even for folks who have taught or treated IBD patients for awhile.
Also a huge shoutout to @IBDPharmD and @GI_PharmD for repping pharmacists.

[David Choi, PharmD @IBDPharmD]

Had a blast with @PDulaiMD the first preconference track @AIBDNetwork 2025 regarding IBD Treatment 101!! Clinical takeaways to give confidence to caring for IBD pts! #aibd2025 #GITwitter #IBD thank you to @MLongMD @DrCoreySiegel @MRegueiroMD

[Shubha Bhat, PharmD @GI_PharmD]

Excited to contribute to this issue to highlight the role of #pharmacists in #GI care!

[Keith Siau @drkeithsiau]

Relative potency of PPIs 💊😅

[David Choi, PharmD @IBDPharmD]

Tremfya is FDA approved for Crohn's disease! This has both IV (200 mg) and subq (400 mg) induction loading dose options followed by subq maintenance dose (100 mg or 200 mg). #GITwitter #IBD

https://t.co/y2Ick4bEcT

[Edward Loftus @EdwardLoftus2]

U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease #Crohns #guselkumab https://t.co/veosbJRQ8Y

[Brendan Miller @_brendanmiller_]

Ribosome profiling (Ribo-Seq) has played a key role in discovering functional smORFs and microproteins, but its effectiveness can still be improved. One way to enhance this method is by integrating proteogenomics, which my lab colleague did here:

https://t.co/brjyUfNGL3

[B. Evana Ghassemi, PHARMD, BCACP, BCPS @IBDPharmacist]

Dr. Satish Rao shares AGA guidelines for IBS:
🚫 Routine stool testing & colonoscopy <45 yrs
🎯 Positive diagnostic strategy recommended
💡 Recommend celiac serologies, CRP, fecal calprotectin, anorectal physiology testing
@GuildConference

[Healio Gastroenterology @HealioGastro]

“I think it’s really exciting in the #IBD space right now because our arsenal of tools 🛠️ is going to continue to grow,” @IBDPharmD said at #CCCongress24.

Check it out ⬇️

https://t.co/XXpDj6sRJX

[Charlie Lees @charlie_lees]

Upadacitinib for acute severe UC

• n is 25
• strange %'s in abstract
• @AmJGastro website down

@ibddoctor can you share ms please

[Greg Zumach, PharmD, BCPS @GZPharmD]

Had an amazing experience at #CCCongress24 in Las Vegas! Great job IBD pharmacists. Going to make waves in patient care!

[Greg Zumach, PharmD, BCPS @GZPharmD]

Excited for next week’s Crohn’s and Colitis Congress.
Fellow pharmacists, who is planning to be in Vegas? #CCCongress24

[ACCP GILN PRN @accpGILNprn]

https://t.co/UUzsR5LunD

Vonoprazan has been FDA approved for the treatment and maintenance of erosive esophagitis based on a phase 3 trial demonstrating superiority vs. lansoprazole. Superiority was driven by patients with more severe disease.

[Greg Zumach, PharmD, BCPS @GZPharmD]

Excited for next week’s Crohn’s and Colitis Congress.
Fellow pharmacists, who is planning to be in Vegas? #CCCongress24

[ACCP GILN PRN @accpGILNprn]

Major update! Subcutaneous infliximab-dyyb has been approved for the maintenance treatment of Crohn's disease and ulcerative colitis. Subcutaneous infliximab-dyyb should be started after completion of IV infusion induction therapy.

https://t.co/x80lGyNrS8

[David Choi, PharmD @IBDPharmD]

What an exciting time for IBD with all these new therapies! Mirikizumab (Omvoh) is FDA Approved for Ulcerative colitis!! #GItwitter #IBD https://t.co/h0k2n1qdZq

[David Choi, PharmD @IBDPharmD]

Velsipity (Etrasimod) if now FDA approved for ulcerative colitis! #gitwitter #IBD

[David Choi, PharmD @IBDPharmD]

Thank you @CrohnsColitisFn and @EugeneYenMD for supporting IBD pharmacists for education! We had an amazing IBD pharmacist break out education. #GITwitter #IBD #ibdpharmacistnetwork